key: cord-0951368-cnir3fx1
authors: Kelly, Jeannie C.; Carter, Ebony B.; Raghuraman, Nandini; Nolan, Lila S.; Gong, Qingqing; Lewis, Angela N.; Good, Misty
title: Anti–severe acute respiratory syndrome coronavirus 2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination
date: 2021-03-31
journal: Am J Obstet Gynecol
DOI: 10.1016/j.ajog.2021.03.031
sha: be3433a3dbc9ee1347f3813b0bb5353daa9e946c
doc_id: 951368
cord_uid: cnir3fx1

N/A.

Antiesevere acute respiratory syndrome coronavirus 2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination OBJECTIVE: In December 2020, 2 lipid nanoparticleformulated, nucleoside-modified messenger RNAebased vaccines received emergency use authorization by the US Food and Drug Administration, after their trials demonstrated 94% to 95% efficacy in preventing coronavirus disease 2019 (COVID-19). 1 Although no lactating people were included in the vaccine trials, national organizations support vaccination of this population, suggesting potential infant protection by passive transfer of maternal antibodies. 1,2 However, there are no published data to support this theoretical benefit. We sought to characterize breast milk levels of antiesevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in lactating people undergoing COVID-19 vaccination.

Participants were prospectively recruited during phase IA rollout of the COVID-19 vaccine at a tertiary care center, after institutional review board approval. Inclusion criteria included lactation and planned vaccination with the Pfizer-BioNTech (Pfizer, Inc, New York, NY)/BNT162b2 vaccine (BioNTech SE, Mainz, Germany). After obtaining informed consent, participants provided frozen breast milk samples at the following time points of vaccination: before, within the first 24 hours, and the following week. Samples were assessed for SARS-CoV-2 RNA by quantitative real-time polymerase chain reaction and antispike immunoglobulin (Ig) G and IgA by an enzyme-linked immunosorbent assay.

A total of 5 subjects and 29 human milk samples were included in the analysis. Subject characteristics are reported in Figure 1 , A. All prevaccine milk samples tested negative for SARS-CoV-2 RNA, as defined by the cycle threshold value of >40 for the N1 target (Figure 1, B) . Antispike IgG and IgA levels were significantly elevated relative to the prevaccine baseline at all time points. Antispike protein IgG remained sustained at a significant elevation beginning at 20 days after the first dose compared with the prevaccine baseline (P¼.0061), through the final milk sample (day 30e39 P¼.0095, >40 days P¼.0040; (Figure 1, C) . Levels of antispike protein IgA were significantly elevated from baseline, starting 2 weeks after the first dose (P¼.0286) through to the final sample (day 20e29 P¼.0121, day 30e39 P¼.0095, >40 days P¼.0040); however, individual level data suggest a possible gradual decline in antispike IgA in human milk over time after the second dose (Figure 1, D) .

We characterize longitudinal breast milk levels of antispike IgG/A following Pfizer-BioNTech/BNT162b2 vaccination, demonstrating sustained elevation of IgG/IgA levels. This response is similar to previous studies on maternal vaccination, which have shown high levels of breast milk IgA/ G production for up to 6 months after vaccination for influenza and pertussis. 3, 4 A concurrent decrease in infant respiratory illness rates suggest that maternal vaccination confers protection against infection in breastfed infants. 3 Thus, the Pfizer-BioNTech/BNT162b2 vaccination may also confer protection against COVID-19 to breastfed infants as well. Although vaccination remains one of the most crucial interventions to control infection spread, vaccine hesitancy remains a barrier to widespread uptake. 5 Our study is limited by a small number of participants, but we report data that suggest a potential immune benefit to infants of lactating people up to 80 days after COVID-19 vaccination. Further studies are needed to characterize the length of antibody production in breast milk and the effect on infant infection rates after maternal COVID-19 vaccination.

-

Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States

American College of Obstetricians and Gynecologists. Vaccinating pregnant and lactating patients against COVID-19

IgA and neutralizing antibodies to influenza A virus in human milk: a randomized trial of antenatal influenza immunization

Impact of pertussis-specific IgA, IgM, and IgG antibodies in mother's own breast milk and donor breast milk during preterm infant digestion

The VACCINES act: deciphering vaccine hesitancy in the time of COVID-19

The authors would like to thank Chanill Henley for her assistance in the completion of this project.